Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CDK4 inhibitors in metastatic breast cancer

Rationale to target CDK4

Date

09 Sep 2017

Session

CDK4 inhibitors in metastatic breast cancer

Topics

Cytotoxic Therapy;  Targeted Therapy;  Breast Cancer

Presenters

Ben O'Leary

Authors

B. O'Leary

Author affiliations

  • -, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.